Enrico Sammarco

Livorno, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Journal: Expert review of anticancer therapy

Published: June 30, 2026

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Journal: Cancers

Published: December 21, 2025

Mixed endometrial carcinoma: is it time to profile the two components separately?

Mixed endometrial carcinoma: is it time to profile the two components separately?

Journal: Frontiers in oncology

Published: October 30, 2025

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.

Journal: European urology open science

Published: October 16, 2025

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Journal: Oncology research

Published: September 25, 2025

177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 12, 2025

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.

Journal: Clinical & experimental metastasis

Published: May 24, 2025

First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm.

First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm.

Journal: Cells

Published: April 29, 2024

Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm.

Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm.

Journal: Clinical genitourinary cancer

Published: February 27, 2024

Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.

Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.

Journal: Medical oncology (Northwood, London, England)

Published: February 10, 2024

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions.

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions.

Journal: Cancers

Published: May 16, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026